scholarly journals Count Every Newborn: EN-INDEPTH study to improve pregnancy outcome measurement in population-based surveys

2021 ◽  
Vol 19 (S1) ◽  
Author(s):  
Stephen M. Tollman ◽  
Peter Byass ◽  
Peter Waiswa ◽  
Hannah Blencowe ◽  
Judith Yargawa ◽  
...  
2006 ◽  
Vol 9 (2) ◽  
pp. 279-284 ◽  
Author(s):  
Michael F. G. Murphy ◽  
Rachel E. Neale ◽  
Kate Hey ◽  
Valerie A. Seagroatt ◽  
Michael J. Goldacre ◽  
...  

AbstractPregnancy outcome and characteristics of women who conceive following subfertility treatment remains a subject of great interest. We analyzed these variables among 199 women who delivered a registerable twin birth compared with 1773 women who delivered a naturally conceived twin birth in a population-based obstetric cohort drawn from around Oxford, England. Treatment was restricted to conceptions involving simple ovulation induction only. Treated mothers were of significantly higher social class and older, more likely to deliver girls and to be delivered by cesarean section, and significantly less likely to be smokers at the time of antenatal booking and to have delivered previous pregnancies. Pregnancy outcome was similar between the two groups for most measures, with the exception of birthweight which was lower in treated twins, though not significantly so. Overall the results are reassuring with respect to outcome in twin pregnancies following simple ovulation induction.


2001 ◽  
Vol 185 (6) ◽  
pp. S186
Author(s):  
Michael Paidas ◽  
Gabriele Urban ◽  
Edward Kuczynski ◽  
Andrei Rebarber ◽  
Jeanine Maturi ◽  
...  

2016 ◽  
Vol 115 (02) ◽  
pp. 285-290 ◽  
Author(s):  
Savino Sciascia ◽  
D. Ware Branch ◽  
Roger A. Levy ◽  
Saskia Middeldorp ◽  
Sue Pavord ◽  
...  

SummaryThe use of low-dose aspirin and heparinoids has improved the pregnancy outcome in obstetric antiphospholipid syndrome (APS). However, current treatment fails in 20–30 % of APS pregnancies, raising the need to explore other treatments to improve obstetrical outcome. Hydroxychloroquine (HCQ) is widely used in patients with autoimmune diseases, mainly systemic lupus erythematous (SLE), due to its anti-inflammatory, anti-aggregant and immune-regulatory properties. Evidence from in vitro and animal models suggests a potential protective effect of HCQ in obstetric APS. Pending the availability of prospective trials, we aimed to systematically review the available evidence and to assess the clinical judgment of a panel of experts regarding the use of HCQ in improving pregnancy outcome in women with anti-phospholipid antibodies (aPL). Clinical data on the ability of HCQ to improve pregnancy outcome in women with aPL are very limited in the available literature. Only one cohort study evaluating maternal and fetal outcome of pregnancy in patients with SLE who were exposed to HCQ was identified. Four of 14 (29 %) treated with HCQ patients had pregnancy failure, compared with six of 24 (25 %) of patients not treated with HCQ. However, the effect of HCQ was not adjusted for the use of other medications such as aspirin, heparins or steroids. Selected experts were contacted by e-mail and asked to review the summary of the evidence provided by the working group and to briefly answer each of the proposed questions. Overall, the panel of experts agreed that adding HCQ could be considered in selected cases or after failure of standard treatment with aspirin and a heparin agent. Specifically, the majority of experts considered adding HCQ in specific scenarios, such as women with previous thrombosis (either arterial and/or venous), and/or with previous ischaemic placenta-mediated complications. Prospective studies are necessary before the use of HCQ during pregnancy in women with aPL should be routinely recommended for clinical practice.


Hepatology ◽  
2018 ◽  
Vol 68 (2) ◽  
pp. 625-633 ◽  
Author(s):  
Jonas F. Ludvigsson ◽  
Hanns-Ulrich Marschall ◽  
Hannes Hagström ◽  
Jonas Höijer ◽  
Olof Stephansson

Sign in / Sign up

Export Citation Format

Share Document